Group 1 - Biotech stocks experienced significant gains in after-hours trading, with several companies showing strong percentage increases despite no new company-specific news [1][2][3][4] - Coherus Oncology, Inc. (CHRS) rose by 9.09% to close at $1.73, adding $0.14 in extended trading [1] - Sensei Biotherapeutics, Inc. (SNSE) surged 10.06% to finish at $12.47, gaining $1.14 [1] - Cue Biopharma, Inc. (CUE) advanced 9.37% to $0.40, increasing by $0.034 [1] - Alpha Tau Medical Ltd. (DRTS) increased by 3.35% to $7.41, up $0.24, with recent focus on new leadership [2] - Cingulate Inc. (CING) edged up 1.49% to close at $5.45, gaining $0.08 [3] - uniQure N.V. (QURE) posted a notable 9.96% jump to $24.95, adding $2.26 in after-hours trading [3] - IO Biotech, Inc. (IOBT) gained 4.19% to $0.50, up $0.020, while exploring strategic alternatives including mergers and asset sales [4]

Core Insights - The company is focused on transforming into an innovative oncology firm that aims to overcome immune resistance in cancer treatment [3] Company Progress - The CEO provided an update on the company's progress over the past 12 months since the last conference [2] - The cornerstone therapy for the company is LOQTORZI, which serves as a revenue multiplier in conjunction with their PD-1 backbone [3] Promising Assets - The company is developing Tagmokitug, a promising asset in the evolving class of Treg depleters, highlighting its mechanism of action and potential as a new treatment paradigm [3] - Casdozokitug was also mentioned as part of the company's portfolio, indicating ongoing development in innovative cancer therapies [3]

Coherus Oncology FY Conference Summary Company Overview - **Company**: Coherus Oncology (NasdaqGM:CHRS) - **Event**: FY Conference at the 44th JPMorgan Healthcare Conference - **Date**: January 13, 2026 Key Points Company Transformation and Strategy - Coherus has evolved into an innovative oncology company focused on overcoming immune resistance in cancer treatment, with Lactose as a cornerstone therapy [2][3] - The acquisition of Surface Oncology in September 2023 provided global rights to promising products CHS-114 (a CCR8 Treg depleter) and Casdozokitug [4] - The company divested its biosimilar business, raising approximately $800 million, which helped pay down $480 million in debt and support ongoing clinical studies [5] Product Pipeline and Market Opportunities - Coherus's pipeline represents a market opportunity of approximately $29 billion, with significant potential in both U.S. and ex-U.S. markets [9] - **Lactose**: A next-generation PD-1 therapy showing high activity, particularly in low PD-1 states, with a five-year survival rate improvement from 34 months to 65 months when combined with chemotherapy [11] - **CHS-114**: Positioned as a best-in-class Treg depleter, targeting Tregs in the tumor microenvironment to enhance T cell infiltration [15][16] - **Casdozokitug**: A first-in-class IL-27 antagonist showing a 38% overall response rate in hepatocellular carcinoma (HCC) studies, with ongoing trials expected to yield data in mid-2026 [24][25] Financial Projections and Sales Growth - Coherus anticipates revenue growth for Lactose, projecting $150-$200 million by mid-2028, supported by a strong sales trajectory and market penetration strategies [12][49] - The company has successfully increased demand growth quarter-over-quarter, exceeding initial guidance of 10%-15% [12] Clinical Trials and Data Expectations - Coherus is conducting multiple clinical trials across various cancers, with significant data readouts expected in 2026 [6][19] - The company is focused on optimizing dosing and understanding the best treatment settings for its products, particularly for Tecmo Kito and Casdozokitug [31][32] Competitive Landscape and Differentiation - Coherus emphasizes the selectivity and potency of its products, particularly Tecmo Kito, which is the only selective CCR8 binder disclosed, differentiating it from competitors [33][34] - The company is pursuing partnerships to enhance the development of its therapies, particularly in combination with other modalities like T-cell engagers and CAR-T therapies [40][41] Challenges and Market Dynamics - The company faces challenges in educating community physicians about its products due to the rarity of the diseases treated, necessitating sophisticated outreach strategies [48][49] - Coherus is aware of the competitive landscape and is strategically positioning its products to overcome resistance mechanisms in solid tumors [43] Future Outlook - Coherus is optimistic about 2026, with a strong focus on data generation and strategic partnerships to drive growth and enhance shareholder value [29][30] Conclusion Coherus Oncology is strategically positioned for growth in the oncology market with a robust pipeline and a focus on innovative therapies. The company is actively working to enhance its market presence and drive shareholder value through strategic partnerships and clinical advancements.

Financial Results Presentation - Coherus Oncology, Inc. will present preliminary unaudited net revenues for the quarter and fiscal year ended December 31, 2025, at the 43rd Annual J.P. Morgan Healthcare Conference[4] - The financial closing procedures for the quarter and fiscal year ended December 31, 2025, are not yet complete, which may lead to significant changes in the preliminary results[6] - The independent registered public accounting firm has not reviewed or audited the financial results presented in this announcement[6] Forward-Looking Statements and Risks - Forward-looking statements include projected revenue growth for LOQTORZI, which involves substantial risks and uncertainties[7] - The company highlights risks related to market acceptance of its products by healthcare providers and patients, as well as potential litigation risks[7]

Core Insights - Coherus Oncology, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 10:30 a.m. Pacific Time, with the presentation accessible via webcast [1] - The webcast will be available for replay until February 13, 2026 [2] Company Overview - Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting various cancers [3] - The company's strategy focuses on growing sales of LOQTORZI in nasopharyngeal carcinoma (NPC) and advancing new indications for LOQTORZI in combination with its pipeline candidates and partners [3] Pipeline Details - Coherus' oncology pipeline includes multiple antibody immunotherapy candidates aimed at enhancing immune responses to improve cancer treatment outcomes [4] - Tagmokitug, a selective cytolytic anti-CCR8 antibody, is currently in Phase 1b/2a studies for advanced solid tumors, including head and neck squamous cell carcinoma, colorectal cancer, gastric cancer, and esophageal cancer [4] - Casdozokitug, a novel IL-27 antagonistic antibody, is being evaluated in a Phase 2 study for first-line hepatocellular carcinoma [4]

Company Overview - Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI (toripalimab-tpzi) [3] - The company has a pipeline that includes two mid-stage clinical candidates targeting various cancers such as liver, lung, head & neck, and colorectal [3] Upcoming Events - Senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 10:30 a.m. Pacific Time [1] - The presentation and Q&A session will be accessible via webcast, available for replay until February 13, 2026 [1][2] Pipeline and Research - Coherus' innovative oncology pipeline includes multiple antibody immunotherapy candidates aimed at enhancing immune responses for better cancer treatment outcomes [4] - Tagmokitug, a highly selective cytolytic anti-CCR8 antibody, is currently in Phase 1b/2a studies for advanced solid tumors [4] - Casdozokitug, a novel IL-27 antagonistic antibody, is being evaluated in a Phase 2 study for first-line hepatocellular carcinoma [4]

Core Viewpoint - Coherus Oncology has introduced its investigational anti-CCR8 monoclonal antibody, tagmokitug, which shows high selectivity and efficacy in targeting CCR8+ T regulatory cells in solid tumors, indicating its potential as an anticancer treatment [1][3][4]. Group 1: Scientific Evidence and Mechanism - The publication in Molecular Cancer Therapeutics highlights tagmokitug's picomolar binding affinity and its ability to selectively eliminate CCR8+ T regulatory cells without off-target binding [1][3]. - Preclinical and clinical studies demonstrate that tagmokitug induces significant tumor regression in mouse models, especially when combined with anti-PD-1 antibody treatment [4]. - The first-in-human clinical study confirms that tagmokitug leads to selective reductions in CCR8+ Tregs in cancer patients, establishing proof of mechanism [5]. Group 2: Clinical Development and Pipeline - Tagmokitug is currently undergoing Phase 1b/2a clinical trials in combination with the PD-1 inhibitor toripalimab and chemotherapy for patients with various solid tumors [6][8]. - Coherus Oncology's pipeline includes multiple antibody immunotherapy candidates aimed at enhancing immune responses to improve cancer treatment outcomes [8]. Group 3: Company Overview - Coherus Oncology is a commercial-stage innovative oncology company with an approved PD-1 inhibitor, LOQTORZI®, and a promising pipeline targeting various cancers [7]. - The company's strategy focuses on growing sales of LOQTORZI in nasopharyngeal carcinoma and advancing new indications in combination with its pipeline candidates [7].

Coherus Oncology ( CHRS ) is a small-cap oncology company that has given me optimism, particularly as they have leveraged asset sales to fund ongoing research while also maintaining a commercial pipeline, as II have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of inve ...

Coherus Oncology Conference Summary Company Overview - **Company**: Coherus Oncology (NasdaqGM:CHRS) - **Focus**: Transitioned from a biosimilar company to a commercial-stage innovative oncology company with a focus on immuno-oncology pipeline, particularly PD-1 inhibitors and novel therapies [3][4][5] Key Products and Pipeline - **Toripalimab**: FDA-approved next-generation PD-1 inhibitor, cornerstone of the oncology pipeline [4][5] - **Casdozokitug**: First-in-class anti-IL27 therapy showing promise in liver cancer and other tumor types [11][12] - **Tagmukitug**: Cytolytic antibody targeting CCR8, showing potential in various solid tumors [53][54] Clinical Data and Efficacy - **Casdozokitug**: - Phase 1 trial showed manageable safety profile with no dose-limiting toxicities (DLTs) [16] - Monotherapy activity observed in squamous non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC) [17] - In combination with Atizo and Bev for hepatocellular carcinoma (HCC), showed an overall response rate (ORR) of 38% and a complete response (CR) rate of 17%, compared to historical controls of 30% and 8% respectively [20][21] - Responses observed irrespective of viral etiology, indicating broad applicability [22] - **Tagmukitug**: - Demonstrated ability to deplete CCR8-positive T regulatory cells in tumors, leading to increased CD8 T cell activity [56] - Early data from head and neck cancer patients showed promising responses in heavily pre-treated individuals [62] Safety and Tolerability - **Casdozokitug**: Safety profile encouraging, with no significant increase in immune-related adverse events compared to standard treatments [26][27] - **Tagmukitug**: Selective targeting of CCR8 with a favorable safety profile, avoiding off-target toxicity seen in other CCR8 programs [58][59] Market Position and Future Outlook - **Market Strategy**: Coherus aims to leverage its innovative pipeline to establish a strong position in the oncology market, focusing on underserved patient populations [5][9] - **Upcoming Milestones**: - Initial data for the Casdozokitug triplet combination expected in mid-2026 [47] - Continued development of Tagmukitug across multiple tumor types with data anticipated throughout 2026 [65] Conclusion - Coherus Oncology is positioned for a data-rich 2026 with promising clinical trials and innovative therapies that could significantly impact cancer treatment, particularly in HCC and other solid tumors [71]

Core Insights - Coherus Oncology announced significant six-year overall survival follow-up results from the Phase 3 JUPITER-02 trial, highlighting the survival advantage of LOQTORZI in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma [1][2][7] Group 1: Clinical Trial Results - The Phase 3 JUPITER-02 trial demonstrated that patients receiving LOQTORZI plus chemotherapy achieved a median overall survival of 64.8 months, compared to 33.7 months for those receiving chemotherapy alone, indicating a 31-month improvement and a 38% reduction in the risk of death [2][4][7] - The long-term follow-up results reinforce the potential of LOQTORZI to transform outcomes for patients with recurrent or metastatic nasopharyngeal carcinoma [2][4][6] Group 2: Clinical Implications - The findings suggest a meaningful clinical benefit for patients with RM-NPC, an aggressive cancer with typically limited long-term survival under standard chemotherapy [4][6] - Oncologists may consider incorporating LOQTORZI into first-line treatment regimens to enhance survival outcomes for patients facing challenging prognoses [6][7] Group 3: Company Strategy and Pipeline - Coherus Oncology is focused on advancing its pipeline, which includes LOQTORZI as a next-generation PD-1 inhibitor, aiming to deliver first- and best-in-class therapies [7][35] - The company is strategically positioned to grow sales of LOQTORZI in nasopharyngeal carcinoma and explore new indications through collaborations and proprietary combinations [35][36]